Research Jun 02, 2026

Peptides for Fatigue: MOTS-c & Tesamorelin Research

 

The Biology of Fatigue:
Peptides Researchers Are Studying

A mechanism-of-action explainer on how MOTS-c and Tesamorelin interact with the cellular and hormonal pathways that govern energy production, metabolic stress, and physical capacity.

Research Use Only: This article is intended for educational and informational purposes only. All compounds discussed are strictly for laboratory research use. Not for human consumption or veterinary use.

Fatigue at a cellular level is not simply tiredness. It is a state of compromised energy availability, impaired mitochondrial function, or dysregulated hormonal signalling that limits a cell's ability to sustain normal metabolic output. Researchers investigating what peptides interact with fatigue-related pathways have increasingly focused on two distinct biological targets: the mitochondrial energy-sensing system, and the growth hormone axis. Two peptides have emerged as particularly relevant research models for the question of what is a good peptide that helps with fatigue: MOTS-c, a peptide produced inside the mitochondria themselves, and Tesamorelin, a synthetic analogue of a natural hormone that governs growth hormone release.

This article outlines the published molecular biology of both compounds, covering what receptors they interact with, what cellular pathways they activate, and what animal model data has suggested about their relationship with energy metabolism and physical capacity.

MOTS-c: A Signal From Inside the Mitochondria

What Is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a short peptide of just 16 amino acids, encoded not by nuclear DNA like most proteins but by the mitochondria's own genome. This makes it part of a rare class of compounds called mitochondrial-derived peptides (MDPs). What makes MOTS-c particularly interesting to researchers is that it appears to function as an internal communication signal. When cellular energy becomes stressed, MOTS-c is produced and travels from the mitochondria outward into the cytoplasm, and under conditions of sufficient stress, into the cell's nucleus, where it can directly influence how genes related to energy and stress adaptation are expressed.

MOTS-c is significantly expressed in response to stress or exercise and translocates to the nucleus, where it regulates the expression of stress adaptation-related genes with antioxidant response elements. It mainly acts through the Folate-AICAR-AMPK pathway, thereby influencing energy metabolism, insulin resistance, and inflammatory response. Wan W et al. Journal of Translational Medicine, 2023. DOI: 10.1186/s12967-023-03885-2

The AMPK Pathway: The Cell's Energy Sensor

To understand how MOTS-c relates to fatigue biology, it helps to understand AMPK, or AMP-activated protein kinase. Think of AMPK as a cellular fuel gauge. When energy levels inside a cell drop, AMPK switches on and signals the cell to stop storing energy and start generating it, promoting fat burning, increasing glucose uptake into muscle cells, and stimulating the creation of new mitochondria. MOTS-c activates AMPK through a well-documented biochemical sequence:

01
MOTS-c moves into the cytoplasm and interferes with the folate cycle, a set of chemical reactions involved in building purines (components of DNA and energy molecules).
02
This causes a molecule called AICAR to accumulate, a well-characterised direct activator of AMPK used in laboratory research to study AMPK-dependent effects in isolation.
03
AICAR activates AMPK, triggering downstream effects including increased glucose transport into muscle cells, enhanced fat oxidation, and suppression of energy-wasting processes.
04
Under sufficient metabolic stress, MOTS-c translocates further into the cell nucleus, directly regulating genes associated with stress adaptation and metabolic resilience. This retrograde signal from the mitochondria to the genome is a key feature of its mechanism.
Why this matters for fatigue research

Standard AMPK activation requires genuine energy depletion, meaning cellular ATP must drop for the sensor to fire. MOTS-c bypasses this requirement, activating the same metabolic programming without the cell needing to be in an energy deficit. Researchers have described this as a distinguishing feature for exercise-mimetic research models.

What Animal Model Research Has Observed

The most cited study in this area, published in Nature Communications in 2021, examined MOTS-c across multiple age groups of mice. Researchers reported that MOTS-c administration significantly enhanced physical performance in young, middle-aged, and aged animals. In the aged group, a two-week treatment period was associated with approximately a two-fold increase in measured physical capacity. The study also confirmed that in human subjects, acute exercise induced a measurable rise in circulating MOTS-c levels, establishing a direct connection between physical exertion and endogenous production of the peptide.

Mitochondrial-encoded MOTS-c significantly enhances physical performance in young, middle-age, and old mice. MOTS-c regulates nuclear genes related to metabolism and proteostasis, skeletal muscle metabolism, and myoblast adaptation to metabolic stress. In humans, exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation. Reynolds JC et al. Nature Communications, 2021. DOI: 10.1038/s41467-020-20790-0

A separate study published in Physiological Reports in 2022 found that MOTS-c protein expression increased 1.5 to 5-fold in rodent skeletal muscle following 4–8 weeks of voluntary running, and that this increase was sustained for several weeks after training ceased. A single administered dose also increased total running time by 12% and running distance by 15% in untrained animals during an acute exercise test.

A single dose of MOTS-c administered to untrained mice improved total running time (12% increase) and distance (15% increase) during an acute exercise test. Hyatt JPK. Physiological Reports, 2022. DOI: 10.14814/phy2.15377

Tesamorelin: The Growth Hormone Axis and Metabolic Energy

What Is Tesamorelin?

Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), a peptide naturally produced in the hypothalamus that signals the pituitary gland to release growth hormone (GH). The synthetic version is structurally modified for greater stability and resistance to enzymatic breakdown than native GHRH, allowing it to persist longer in research models.

Researchers interested in what is a good peptide that helps with fatigue from a hormonal perspective frequently examine Tesamorelin because of its position at the top of the GH/IGF-1 axis, a hormonal cascade with well-established connections to body composition, metabolic rate, and cellular energy production.

How Tesamorelin Activates the GH Axis

01
Tesamorelin binds to the GHRH receptor (GHRH-R), a G-protein-coupled receptor on specialised cells (somatotrophs) in the anterior pituitary gland. Published reviews note Tesamorelin demonstrates greater metabolic selectivity than ghrelin receptor agonists.
02
Binding activates the adenylate cyclase–cAMP signalling cascade inside the pituitary cell, triggering pulsatile release of growth hormone into circulation. This mimics the natural secretion pattern rather than producing a continuous supraphysiological spike.
03
Released GH travels to the liver and peripheral tissues, stimulating production of IGF-1 (Insulin-like Growth Factor 1), the primary mediator of GH's downstream effects including protein synthesis, lipolysis (fat breakdown), and cellular energy regulation.
04
Because Tesamorelin preserves the natural IGF-1 feedback loop, where rising IGF-1 signals the pituitary to reduce GH output, researchers have observed that IGF-1 levels in study models tend to remain within normal physiological ranges. This distinguishes it from exogenous GH administration.
Tesamorelin activates GHRH receptors in the pituitary, leading to synthesis and release of growth hormone that acts on multiple cells including hepatocytes, where it stimulates production of IGF-1. IGF-1 mediates many of the effects of growth hormone, including growth, inhibition of programmed cell death, glucose uptake, and lipolysis. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NIH/NCBI Bookshelf, 2018.

The Connection to Energy and Physical Capacity

Growth hormone and IGF-1 are directly involved in the metabolic processes that determine how efficiently cells generate and use energy. Laboratory models investigating glucose utilisation and mitochondrial energy function have incorporated Tesamorelin to evaluate how growth hormone signalling influences metabolic enzymes and mitochondrial biogenesis, the process by which cells create new mitochondria.

A clinical research study published in the Journal of Clinical Endocrinology & Metabolism examined the effects of Tesamorelin on GH pulsatility and found that the compound significantly augmented both basal and pulsatile GH secretion. Researchers also observed that despite significant increases in IGF-1, peripheral insulin-stimulated glucose uptake was preserved, a finding relevant to research on metabolic health models where energy dysregulation and fatigue-like states are observed together.

Tesamorelin treatment augments basal and pulsatile GH secretion. Although tesamorelin significantly increases IGF-1, peripheral insulin-stimulated glucose uptake appears to be preserved. Falutz J et al. Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20943777
Why the GH/IGF-1 axis is relevant to fatigue research

Growth hormone deficiency states are consistently associated in the published literature with reduced physical capacity, altered body composition, and impaired energy metabolism. Tesamorelin restores pulsatile GH secretion through the natural pituitary pathway rather than bypassing it, making it a useful model for studying GH-axis restoration without the artefacts of supraphysiological GH exposure.

Two Pathways, One Research Question

Researchers approaching the question of what is a good peptide that helps with fatigue at a mechanistic level are asking which biological bottleneck is most relevant to their model. MOTS-c and Tesamorelin address distinct but complementary layers of the same system.

MOTS-c operates at the most fundamental level, working directly within the mitochondria themselves. Its activation of AMPK-mediated metabolic programming acts directly on the cellular machinery responsible for generating ATP. Animal model findings suggest this pathway is particularly relevant in the context of age-related physical decline and metabolic stress states, where endogenous MOTS-c production is known to fall with age.

Tesamorelin operates at the hormonal coordination layer, signalling through the pituitary to restore a pattern of GH and IGF-1 activity that governs how cells allocate energy resources, build and maintain lean tissue, and manage fat stores. Researchers have proposed that dysregulation of this axis is a significant contributor to the reduced energy and physical capacity phenotypes observed in models of metabolic dysfunction and ageing.

Together, these two research compounds represent different entry points into the biology of cellular energy: one approaching from the mitochondrial level upward, the other from the endocrine level downward.


Summary

Published preclinical research has established clear mechanistic rationales for investigating both MOTS-c and Tesamorelin in the context of energy metabolism and physical capacity. MOTS-c activates the AMPK energy-sensing pathway via the folate–AICAR route, with animal model data demonstrating measurable effects on physical performance and skeletal muscle metabolism across age groups. Tesamorelin engages the GHRH receptor to restore pulsatile growth hormone secretion, activating the GH/IGF-1 axis in a manner that preserves normal feedback regulation. Both compounds remain active areas of laboratory investigation. Neither has received regulatory approval for the management of fatigue or related conditions in humans, and all data referenced in this review originates from animal model or controlled laboratory settings.